Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.
收藏数据链接：
官方服务：
资源简介：
Orphan Drug (OD) legislation has been implemented with regulatory and financial incentives to encourage drug innovation in order to treat rare diseases. This study aims to test whether OD Designations (ODD) granted by the Food and Drug Administration (FDA) to pharmaceutical and biotechnology start
提供机构：
美国国家经济研究局创建时间：
2017-11-01
